Aldh3a1 Antibody

What is ALDH3A1 and why is it significant in research?

ALDH3A1 (Aldehyde Dehydrogenase 3 family, member A1) is a 51-55 kDa enzyme belonging to the ALDH superfamily with both nuclear and cytosolic localization. Its significance stems from its multifunctional roles including detoxification of medium-chain aldehydes, UV light absorption in corneal tissue, antioxidant activity through NADPH production, and cell cycle modulation via reduced cyclin-dependent kinase activity . The enzyme's UVB light absorption capability in the cornea induces protein aggregation and inactivates its enzymatic function, representing a unique protective mechanism . This diverse functionality makes ALDH3A1 a critical target in multiple research areas including cancer biology, oxidative stress responses, and corneal protection mechanisms.

What antibody formats are available for ALDH3A1 detection?

Several validated antibody formats are available for ALDH3A1 detection:

The selection depends on experimental design requirements and target species. For multi-color immunofluorescence applications, researchers should consider host species compatibility with other primary antibodies in their panel .

How should I validate a new ALDH3A1 antibody for my research?

Proper validation should include:

• Western blot analysis using known positive controls (A549 lung carcinoma cells, human lung, stomach, or liver tissue)

• Expected molecular weight confirmation (~55 kDa under reducing conditions)

• Immunostaining pattern analysis - ALDH3A1 typically shows cytoplasmic and sometimes nuclear localization

• Comparison with published literature results

• Negative controls including:

  • Secondary antibody-only controls

  • Tissues/cells known to lack ALDH3A1 expression

  • Blocking peptide competition assays where available

For enhanced validation rigor, compare staining patterns across multiple antibodies targeting different ALDH3A1 epitopes.

What are the optimal conditions for Western blot detection of ALDH3A1?

Western blot optimization for ALDH3A1 requires several key considerations:

• Sample preparation: Use RIPA or similar lysis buffers containing protease inhibitors

• Running conditions: Reducing conditions are essential

• Protein amount: 20-30 μg total protein per lane

• Antibody concentrations:

  • Sheep polyclonal: 0.25 μg/mL

  • Rabbit polyclonal: 0.4 μg/ml

  • Mouse monoclonal: Follow manufacturer recommendations

• Expected size: ~55 kDa band

• Detection system: HRP-conjugated secondary antibodies with appropriate species reactivity

• Positive controls: A549 cells, human lung, liver, and stomach tissue lysates

For enhanced sensitivity when detecting low expression levels, consider using chemiluminescent substrates with longer exposure times or signal enhancement systems.

How do I optimize immunohistochemistry protocols for ALDH3A1 in tissue sections?

For successful ALDH3A1 immunohistochemistry:

• Fixation: Formalin-fixed paraffin-embedded (FFPE) sections work well

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Blocking: Use 5% BSA or serum from secondary antibody host species

• Primary antibody concentration:

  • Sheep polyclonal: 3 μg/mL overnight at 4°C

  • Other antibodies: Follow manufacturer recommendations

• Detection: HRP-DAB systems provide good visualization

• Counterstaining: Hematoxylin for nuclear visualization

• Expected results: Cytoplasmic staining in ALDH3A1-expressing cells, with potential nuclear positivity in some cell types

Comparisons between normal and cancer tissues often reveal differential ALDH3A1 expression patterns, as demonstrated in lung cancer samples where specific cytoplasmic localization in cancer cells was observed .

What are the recommended parameters for immunofluorescence detection of ALDH3A1?

For optimal immunofluorescence results:

• Cell preparation: Immersion fixation methods work well

• Antibody concentration:

  • Sheep polyclonal: 10 μg/mL for 3 hours at room temperature

  • Rabbit polyclonal: 1-4 μg/ml

• Secondary detection: Fluorescent-conjugated secondary antibodies (e.g., NorthernLights 557-conjugated Anti-Sheep IgG)

• Nuclear counterstain: DAPI

• Expected localization: Both cytoplasmic and nuclear staining may be observed

• Positive control: A549 human lung carcinoma cells

For multi-color immunofluorescence, select compatible fluorophores with minimal spectral overlap and perform appropriate compensation controls.

How can I address non-specific staining when using ALDH3A1 antibodies?

Non-specific staining can be minimized through several approaches:

• Optimize primary antibody concentration through titration experiments

• Extend blocking step duration (1-2 hours) and consider alternative blocking reagents

• Increase washing stringency (more washes, higher detergent concentration)

• For tissue sections, perform additional quenching steps for endogenous peroxidase or phosphatase

• Use affinity-purified antibodies when available

• Consider alternative detection systems if background persists

• Verify antibody specificity using competitive blocking with the immunizing peptide

The specificity of commercial antibodies can be verified as some manufacturers test their antibodies against protein arrays containing the target protein plus numerous non-specific proteins .

Why might I observe multiple bands in Western blots using ALDH3A1 antibodies?

Multiple bands may result from:

• ALDH3A1 dimerization - the protein naturally forms homodimers

• Post-translational modifications (phosphorylation, glycosylation)

• Proteolytic degradation during sample preparation

• Cross-reactivity with other ALDH family members

• Splice variants or isoforms

To address this:

• Include protease inhibitors in lysis buffers

• Optimize sample preparation conditions

• Test different reducing agent concentrations

• Compare results from multiple antibodies targeting different epitopes

• Consider the molecular weight of observed bands (ALDH3A1 monomer: ~55 kDa)

How can I use ALDH3A1 antibodies to investigate protein-protein interactions?

For studying ALDH3A1 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use mouse monoclonal antibodies optimized for IP applications

  • Pre-clear lysates to reduce non-specific binding

  • Include appropriate controls (IgG control, input samples)

• Proximity ligation assay (PLA):

  • Combine ALDH3A1 antibody with antibodies against suspected interaction partners

  • Select antibodies from different host species

  • Verify antibody compatibility in multiplexed assays

• Protein-peptide interaction analysis:

  • Peptide ELISA can confirm binding between synthetic peptides and ALDH3A1

  • A dose-dependent increase in absorbance indicates specific binding

  • The WPTYVSPFRSPP peptide showed strong interaction with recombinant hALDH3A1

How can ALDH3A1 antibodies help distinguish between different ALDH family members?

Distinguishing between ALDH family members requires:

• Epitope selection - choose antibodies targeting unique regions of ALDH3A1

• Careful antibody validation against multiple ALDH family members

• Comparison of tissue expression patterns:

  • ALDH3A1: Abundant in stomach, lung, cornea

  • ALDH1A1: Liver, retina

  • ALDH1A2: Developing embryonic tissues

  • ALDH1A3: Salivary gland, stomach, kidney

• Molecular weight differentiation:

  • ALDH3A1: 51-55 kDa

  • ALDH1 isoforms: ~55-56 kDa

• Cellular localization assessment:

  • ALDH3A1: Nuclear and cytosolic

  • Other ALDH members may have distinct compartmentalization patterns

How can I use phage display technology to identify novel peptide ligands for ALDH3A1?

The phage display approach for identifying ALDH3A1-binding peptides involves:

• Coating procedure:

  • Use 75 μg of recombinant ALDH3A1 diluted in coating buffer (0.1 M NaHCO₃, pH 8.6)

  • Coat on a sterile polystyrene plate and incubate for 16h at 4°C

• Blocking and panning:

  • Block with 5 mg/mL BSA in coating buffer for 2h at 4°C

  • Perform multiple rounds of panning with a phage display peptide library

• Clone analysis:

  • After 3 panning cycles, sequence selected phage clones

  • In one study, the peptide WPTYVSPFRSPP appeared in 30 out of 33 samples, indicating strong specific interaction

• Validation:

  • Synthesize identified peptides and confirm binding using peptide ELISA

  • Use serial dilutions of ALDH3A1 protein to demonstrate dose-dependent binding

Table: Peptide frequencies observed in phage display screening for ALDH3A1-binding peptides

What methodologies are available for studying ALDH3A1's role in cancer stem cells?

ALDH3A1's role in cancer stem cells can be investigated using:

• Flow cytometry:

  • Use fluorescently-conjugated ALDH3A1 antibodies for cell sorting

  • Combine with other cancer stem cell markers for co-expression analysis

• Functional assays:

  • Correlate ALDH3A1 expression with tumorsphere formation capacity

  • Measure chemoresistance in ALDH3A1-high versus ALDH3A1-low populations

• Tissue analysis:

  • Compare ALDH3A1 expression between normal lung and lung cancer tissues

  • Analyze subcellular localization changes in cancer progression

  • Cytoplasmic localization in cancer cells has been specifically documented

• Genetic manipulation:

  • Use ALDH3A1 antibodies to validate knockdown/overexpression efficiency

  • Correlate expression levels with cancer stem cell phenotypes

How can I investigate the dual cellular localization of ALDH3A1?

To study ALDH3A1's nuclear and cytosolic distribution:

• Cell fractionation:

  • Separate nuclear and cytoplasmic fractions

  • Perform Western blot analysis with ALDH3A1 antibodies

  • Use compartment-specific markers as controls (e.g., histone H3 for nuclear, GAPDH for cytosolic)

• High-resolution imaging:

  • Conduct confocal immunofluorescence with ALDH3A1 antibodies

  • Co-stain with nuclear and cytoplasmic markers

  • Quantify the relative distribution between compartments

• Stimulus response:

  • Investigate localization changes following UV exposure, oxidative stress, or cell cycle progression

  • Document the aggregation phenomenon observed after UVB exposure

• Functional correlation:

  • Relate subcellular distribution to enzymatic activity

  • Explore potential nuclear functions beyond canonical enzymatic roles

How can ALDH3A1 antibodies contribute to developing targeted cancer therapies?

ALDH3A1 antibodies can advance cancer therapy development through:

• Patient stratification:

  • IHC assessment of ALDH3A1 expression levels in tumor samples

  • Correlation with treatment response and patient outcomes

• Drug target validation:

  • Monitoring ALDH3A1 inhibition efficacy in preclinical models

  • Quantifying changes in expression and localization after treatment

• Therapeutic development:

  • ALDH3A1-binding peptides like WPTYVSPFRSPP could serve as delivery vehicles for targeted therapies

  • Antibody-drug conjugates targeting ALDH3A1-expressing cancer cells

• Mechanistic understanding:

  • Investigating ALDH3A1's protective role against chemotherapy agents

  • Exploring connections between ALDH3A1 and oxidative stress responses

What imaging approaches are most effective for studying ALDH3A1 in complex biological systems?

Advanced imaging for ALDH3A1 research includes:

• Multiplex immunofluorescence:

  • Combine ALDH3A1 antibodies with markers for specific cell types or signaling pathways

  • Use spectral unmixing to resolve multiple fluorophores

• Live-cell imaging:

  • Track ALDH3A1 dynamics in response to cellular stressors

  • Monitor subcellular translocation in real-time

• Super-resolution microscopy:

  • Resolve ALDH3A1 distribution at nanoscale resolution

  • Investigate co-localization with interaction partners

• Tissue clearing techniques:

  • Study ALDH3A1 distribution in intact 3D samples

  • Correlate with tissue architecture and microenvironment